Gilead Sciences (GILD) Projected to Post Quarterly Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD) is projected to issue its quarterly earnings data after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $7.15 billion for the quarter. Gilead Sciences has set its FY24 guidance at $4.25-4.45 EPS and its FY 2024 guidance at 4.250-4.450 EPS.Investors interested in registering for the company’s conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 EPS. On average, analysts expect Gilead Sciences to post $4 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $98.38 on Tuesday. The stock has a 50 day simple moving average of $92.42 and a 200-day simple moving average of $85.96. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $122.61 billion, a PE ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $99.45.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 598,414 shares of company stock worth $55,953,200 over the last three months. Company insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GILD. Mizuho upped their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Barclays raised their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.